相关实验视频

Updated: Jun 22, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

在荷尔蒙受体阳性,人体表皮生长因子受体2-阴性晚期乳腺癌中的capivasertib

Zaheer Qureshi¹, Faryal Altaf², Mikail Khanzada³

¹Assistant Professor of Medicine, The Frank H. Netter M.D. School of Medicine at Quinnipiac University, Bridgeport, Connecticut, USA.

Current problems in cancer

|July 3, 2024

概括

与富尔韦斯特兰特结合的capivasertib在治疗激素受体阳性 (HR +) 乳腺癌方面表现有前途,改善了无进展的生存率,并具有可控的副作用. 建议对这种创新疗法进行进一步的随机对照试验.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

乳腺癌是全球女性最常见的癌症.
激素受体阳性 (HR+) 乳腺癌占病例的很大一部分.
先进的治疗选择对于管理HR+乳腺癌至关重要.

研究的目的:

审查Capivasertib在HR+乳腺癌管理中的作用和疗效.
分析Capivasertib的作用机制,临床试验和比较疗效.
要突出与Capivasertib治疗相关的精确准和生活质量改善.

主要方法:

对Capivasertib.现有的文献进行了深入分析.
对临床试验数据的审查,比较Capivasertib-fulvestrant与单独的fulvestrant.
评估Capivasertib的作用机制,包括它对癌细胞生长和存活的影响.

主要成果:

与富勒弗兰特单独治疗相比,Capivasertib-fulvestrant疗法显示改善了无进展生存率.
该疗法在向特定癌细胞方面表现得精确,抑制了它们的生长并产生了细胞毒性作用.
报告的副作用通常可以通过剂量调整或停止治疗来控制,从而保持患者的生活质量.

结论:

Capivasertib-fulvestrant代表了HR+乳腺癌的潜在创新治疗策略.
组合疗法提供了改善的无进展生存率和有利的副作用概况.
需要进行额外的研究,特别是随机对照试验,以进一步验证其在临床实践中的有效性和作用.

关键词:

乳腺癌乳腺癌乳腺癌在 Capivasertib 中使用.人力资源+人力资源+人力资源没有进展的生存率.

更多相关视频

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...